The abstract is read at the publisher; the summary is JClub's.
Hepatic TLR5 expression is linked to liver fibrosis and mortality in metabolic dysfunction-associated steatohepatitis, and plasma flagellin rises with advanced fibrosis.
- Why it matters: Fibrosis in MASH reflects ongoing hepatocyte injury and inflammation, but the specific TLR that initiates advanced disease is unclear.
- What they did: The study combined clinical data across multiple patient cohorts, single-cell liver transcriptomics, and human in vitro/ex vivo models to test TLR5’s role; it also used hepatocyte TLR5 inhibition and precision-cut liver slices.
- The result: TLR5 signaling drives two parallel hepatocyte injury routes—flagellin- and lipid-induced—and TLR5 inhibition reduces paracrine stellate-cell activation and collagen deposition ex vivo, suggesting a potential therapeutic strategy for advanced MASH fibrosis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.